@article{PatelMurphyHaralmbievaetal.2014,
  author    = {Patel, Suketu and Murphy, Derek and Haralmbieva, Eugenia and Abdulla, Zainalabideen A. and Wong, Kah Keng and Chen, Hong and Gould, Edith and Roncador, Giovanna and Hatton, Chris S. R. and Anderson, Amanda P. and Banham, Alison H. and Pulford, Karen},
  title     = {Increased Expression of Phosphorylated FADD in Anaplastic Large Cell and Other T-Cell Lymphomas},
  series = {Biomarker Insights},
  volume    = {9},
  journal   = {Biomarker Insights},
  issn      = {1177-2719},
  doi       = {10.4137/bmi.s16553},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-121403},
  pages     = {77-84},
  year      = {2014},
  abstract  = {FAS-associated protein with death domain (FADD) is a major adaptor protein involved in extrinsic apoptosis, embryogenesis, and lymphocyte homeostasis. Although abnormalities of the FADD/death receptor apoptotic pathways have been established in tumorigenesis, fewer studies have analyzed the expression and role of phosphorylated FADD (pFADD). Our identification of FADD as a lymphoma-associated autoantigen in T-cell lymphoma patients raises the possibility that pFADD, with its correlation with cell cycle, may possess role(s) in human T-cell lymphoma development. This immunohistochemical study investigated pFADD protein expression in a range of normal tissues and lymphomas, particularly T-cell lymphomas that require improved therapies. Whereas pFADD was expressed only in scattered normal T cells, it was detected at high levels in T-cell lymphomas (eg, 84\% anaplastic large cell lymphoma and 65\% peripheral T cell lymphomas, not otherwise specified). The increased expression of pFADD supports further study of its clinical relevance and role in lymphomagenesis, highlighting phosphorylation of FADD as a potential therapeutic target.},
  language  = {en}
}